within Pharmacolibrary.Drugs.ATC.S;

model S01CC02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.0,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>A combination ophthalmic drug product containing indometacin, a nonsteroidal anti-inflammatory drug (NSAID), with various anti-infective agents, intended to reduce inflammation and prevent or treat infection after eye surgery or in ocular infections. The combination aims to provide both anti-inflammatory and antimicrobial effects in the treatment of ocular conditions. Such combinations have been used in ophthalmology, although specific products may vary by country and are not universally approved worldwide.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies specific to the 'indometacin and antiinfectives' combinations administered ophthalmically have been identified. Pharmacokinetic parameters below are not available in the literature and cannot be accurately estimated due to the unique combination and route; thus, they are left empty.</p><h4>References</h4><ol><li><p>Bisen, AC, &amp; Bhatta, RS (2024). Ocular bioanalysis of moxifloxacin and ketorolac tromethamine in rabbit lacrimal matrix using liquid chromatography-tandem mass spectrometry. <i>Bioanalysis</i> 16(4) 219–232. DOI:<a href=&quot;https://doi.org/10.4155/bio-2023-0233&quot;>10.4155/bio-2023-0233</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38197429/&quot;>https://pubmed.ncbi.nlm.nih.gov/38197429</a></p></li><li><p>Topete, A, et al., &amp; Saramago, B (2018). Improving sustained drug delivery from ophthalmic lens materials through the control of temperature and time of loading. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 117 107–117. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2018.02.017&quot;>10.1016/j.ejps.2018.02.017</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29454097/&quot;>https://pubmed.ncbi.nlm.nih.gov/29454097</a></p></li><li><p>Salvi, V, &amp; Pawar, P (2020). Eudragit RL100 Based Moxifloxacin Hydrochloride and Ketorolac Tromethamine Combination Nanoparticulate System for Ocular Drug Delivery. <i>Pharmaceutical nanotechnology</i> 8(2) 133–147. DOI:<a href=&quot;https://doi.org/10.2174/2211738508666200313140902&quot;>10.2174/2211738508666200313140902</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32167436/&quot;>https://pubmed.ncbi.nlm.nih.gov/32167436</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01CC02;
